Low profile transcatheter heart valve

Information

  • Patent Grant
  • 11744701
  • Patent Number
    11,744,701
  • Date Filed
    Friday, September 11, 2020
    4 years ago
  • Date Issued
    Tuesday, September 5, 2023
    a year ago
Abstract
A prosthetic heart valve comprises a radially collapsible and expandable annular frame and a leaflet structure comprising three leaflets. Each leaflet has an upper edge portion, a curved lower edge portion and two side flaps, wherein each side flap is connected to an adjacent side flap of another leaflet to form commissures of the leaflet structure, with each commissure being attached to the frame. An annular inner sleeve comprises three U-shaped portions positioned along the curved lower edge portions of the leaflets. An annular outer sleeve extends around are outer surface of the frame, wherein the outer sleeve is made of pericardium. The frame is made of Nitinol and the prosthetic valve can be radially crimped to a radially collapsed configuration inside a sheath for delivery into a patient's body and self-expand to a radially expanded configuration when released from the sheath inside the patient's body.
Description
FIELD

The present disclosure relates to implantable devices and, more particularly, to valve prosthetics for implantation into body ducts, such as native heart valve annuluses.


DESCRIPTION OF THE RELATED ART

The human heart can suffer from various valvular diseases. These valvular diseases can result in significant malfunctioning of the heart and ultimately require replacement of the native valve with an artificial valve. There are a number of known artificial valves and a number of known methods of implanting these artificial valves in humans.


Various surgical techniques may be used to repair a diseased or damaged valve. In a valve replacement operation, the damaged leaflets are excised and the annulus sculpted to receive a replacement valve. Due to aortic stenosis and other heart valve diseases, thousands of patients undergo surgery each year wherein the defective native heart valve is replaced by a prosthetic valve, either bioprosthetic or mechanical. Another less drastic method for treating defective valves is through repair or reconstruction, which is typically used on minimally calcified valves. The problem with surgical therapy is the significant insult it imposes on these chronically ill patients with high morbidity and mortality rates associated with surgical repair.


When the valve is replaced, surgical implantation of the prosthetic valve typically requires an open-chest surgery during which the heart is stopped and patient placed on cardiopulmonary bypass (a so-called “heart-lung machine”). In one common surgical procedure, the diseased native valve leaflets are excised and a prosthetic valve is sutured to the surrounding tissue at the valve annulus. Because of the trauma associated with the procedure and the attendant duration of extracorporeal blood circulation, some patients do not survive the surgical procedure or die shortly thereafter. It is well known that the risk to the patient increases with the amount of time required on extracorporeal circulation. Due to these risks, a substantial number of patients with defective valves are deemed inoperable because their condition is too frail to withstand the procedure. By some estimates, more than 50% of the subjects suffering from aortic stenosis who are older than 80 years cannot be operated on for aortic valve replacement.


Because of the drawbacks associated with conventional open-heart surgery, percutaneous and minimally-invasive surgical approaches are garnering intense attention. In one technique, a prosthetic valve is configured to be implanted in a much less invasive procedure by way of catheterization. For instance, U.S. Pat. Nos. 5,411,522 and 6,730,118, which are incorporated herein by reference, describe collapsible transcatheter heart valves that can be percutaneously introduced in a compressed state on a catheter and expanded in the desired position by balloon inflation or by utilization of a self-expanding frame or stent.


An important design parameter of a transcatheter heart valve is the diameter of the folded or crimped profile. The diameter of the crimped profile is important because it directly influences the physician's ability to advance the valve through the femoral artery or vein. More particularly, a smaller profile allows for treatment of a wider population of patients, with enhanced safety.


SUMMARY

The present disclosure is directed toward new and non-obvious methods and apparatuses relating to prosthetic valves, such as heart valves.


In one representative embodiment, an implantable prosthetic valve comprises a radially collapsible and expandable frame, or stent, and a leaflet structure comprising a plurality of leaflets. The leaflet structure has a scalloped lower edge portion that is positioned inside of and secured to the frame. The valve can further include an annular skirt member, which can be disposed between the frame and the leaflet structure such that the scalloped lower edge portion can be attached to an inner surface of the skirt member. Each leaflet can have an upper edge, a curved lower edge and two side flaps extending between respective ends of the upper edge and the lower edge, wherein each side flap is secured to an adjacent side flap of another leaflet to form commissures of the leaflet structure. Each commissure can be attached to one of the commissure attachment posts, and a reinforcing bar can be positioned against each side flap for reinforcing the attachments between the commissures and the commissure attachment posts.


The frame can comprise a plurality of angularly spaced, axial struts that are interconnected by a plurality of rows of circumferential struts. Each row of circumferential struts desirably includes struts arranged in a zig-zag or saw-tooth pattern extending around the circumference of the frame.


In certain embodiments, at least one row, and preferably all rows, of circumferential struts include pairs of circumferential struts extending between two axial struts. Each strut of the pair has one end connected to a respective axial strut and another end interconnected to an adjacent end of the other strut of the same pair by a crown portion such that a gap exists between the adjacent ends of the struts. The angle between the struts of each pair desirably is between about 90 and 110 degrees, with about 100 degrees being a specific example. The frame desirably is made of a nickel-cobalt based alloy, such as a nickel cobalt chromium molybdenum alloy (e.g., MP35N™).


In another representative embodiment, an implantable prosthetic valve comprises a radially collapsible and expandable annular frame and a leaflet structure supported by the frame. The frame can comprise a plurality of interconnected struts defining a plurality of open cells in the frame. The valve further includes an annular cover member disposed on and covering the cells of at least a portion of the frame. The cover member desirably comprises an elastomer, such as silicon, that can expand and stretch when the valve is expanded from a crimped state to an expanded state.


The cover member may be a thin sleeve of silicon that surrounds at least a portion of the frame. Alternatively, the cover member may be formed by dipping at least a portion of the frame in silicon or another suitable elastomer in liquefied form.


In another representative embodiment, a method is disclosed for crimping an implantable prosthetic valve having a frame and leaflets supported by the frame. The method comprises placing the valve in the crimping aperture of a crimping device such that a compressible material is disposed between the crimping jaws of the crimping device and the frame of the valve. Pressure is applied against the compressible material and the valve with the crimping jaws to radially crimp the valve to a smaller profile and compress the compressible material against the valve such that the compressible material extends into open cells of the frame and pushes the leaflets away from the inside of the frame.


The foregoing and other features and advantages of the invention will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of a representative embodiment of a prosthetic heart valve.



FIG. 2 is another perspective view of the prosthetic valve of FIG. 1.



FIG. 3 is another perspective view of the prosthetic valve of FIG. 1.



FIG. 4 is an enlarged view of a section of the valve shown in FIG. 3.



FIG. 5 is a bottom perspective view of the prosthetic valve of FIG. 1 showing the inside of the valve.



FIG. 6 is a top plan view of the prosthetic valve of FIG. 1.



FIG. 6A is an enlarged partial top view of the valve of FIG. 1 illustrating the positioning of the reinforcing bars with respect to the commissure attachment posts of the frame.



FIG. 7 is a perspective view of the frame of the prosthetic valve of FIG. 1.



FIG. 8 is a perspective view of an alternative embodiment of a frame that can be used in the prosthetic valve of FIG. 1.



FIG. 9 is a flattened view of 120-degree segment of the frame shown in FIG. 7.



FIG. 10 is a flattened view of 120-degree segment of the frame shown in FIG. 8.



FIG. 11 is a front view of a reinforcing bar that can be used to reinforce the connection of the valve leaflets to a frame in a prosthetic valve such as shown in FIG. 1.



FIG. 12 is a perspective view of the reinforcing bar of FIG. 11 and a PET sleeve that can be used to cover the bar.



FIG. 13 is a flattened view of a leaflet of the valve shown in FIG. 1.



FIG. 14 is a flattened view of the opposite side of the leaflet showing a reinforcing strip secured adjacent the bottom edge of the leaflet.



FIG. 15 is a top plan view of the leaflet structure of the valve of FIG. 1 prior to attachment to the frame.



FIG. 16 is a flattened view of the skirt used in the valve shown in FIG. 1.



FIG. 17 is a side view of the skirt illustrating suture lines for attaching the skirt to the leaflet structure.



FIG. 18 is a bottom perspective view of the leaflet structure connected to the skirt so as to form a leaflet assembly.



FIG. 19 is a side view of a balloon catheter and a prosthetic valve crimped onto the balloon of the balloon catheter.



FIG. 20 is a front view of a crimping device showing a prosthetic valve positioned in the crimping aperture of the crimping device with a protective sleeve disposed between the valve and the crimping jaws.



FIG. 21 is a front view of the crimping device shown after the crimping jaws are forced inwardly to compress the valve and the protective sleeve.



FIG. 22 is a side view of the valve and protective sleeve after removal from the crimping device.



FIG. 23 is a side view of a prosthetic valve that has been crimped onto a balloon of a balloon catheter without a protective sleeve.



FIG. 24 is a side view of a prosthetic valve that has been crimped onto a balloon of a balloon catheter using a protective sleeve in the manner shown in FIGS. 20-21.



FIG. 25 is a side view of a frame for a prosthetic valve having a silicon skirt, or sleeve, disposed on the outside of the frame.



FIG. 26 is a side view of a frame for a prosthetic valve having a silicon encapsulating layer covering the inside and outside of the frame.



FIG. 27 is a perspective view of a prosthetic valve comprising a frame having a silicon encapsulating layer.



FIG. 28 is a perspective view of the valve of FIG. 27 after it has been crimped to a smaller diameter.



FIG. 29 is a side view of the valve of FIG. 27 after it has been expanded by a balloon catheter.



FIGS. 30A-30C are graphs illustrating the results of respective uniaxial tests performed on respective silicon test strips.



FIGS. 31A-31F are graphs illustrating the results of respective uniaxial tests performed on respective silicon test strips having deliberately introduced tears.





DETAILED DESCRIPTION


FIGS. 1 and 2 illustrate an implantable prosthetic valve 10, according to one embodiment. Valve 10 in the illustrated embodiment generally comprises a frame, or stent, 12, a leaflet structure 14 supported by the frame, and a skirt 16 secured to the outer surface of the leaflet structure. Valve 10 typically is implanted in the annulus of the native aortic valve but also can be adapted to be implanted in other native valves of the heart or in various other ducts or orifices of the body. Valve 10 has a “lower” end 80 and an “upper” end 82. In the context of the present application, the terms “lower” and “upper” are used interchangeably with the terms “inflow” and “outflow”, respectively. Thus, for example, the lower end 80 of the valve is its inflow end and the upper end 82 of the valve is its outflow end.


Valve 10 and frame 12 are configured to be radially collapsible to a collapsed or crimped state for introduction into the body on a delivery catheter and radially expandable to an expanded state for implanting the valve at a desired location in the body (e.g., the native aortic valve). Frame 12 can be made of a plastically-expandable material that permits crimping of the valve to a smaller profile for delivery and expansion of the valve using an expansion device such as the balloon of a balloon catheter. Exemplary plastically-expandable materials that can be used to form the frame are described below. Alternatively, valve 10 can be a so-called self-expanding valve wherein the frame is made of a self-expanding material such as Nitinol. A self-expanding valve can be crimped to a smaller profile and held in the crimped state with a restraining device such as a sheath covering the valve. When the valve is positioned at or near the target site, the restraining device is removed to allow the valve to self-expand to its expanded, functional size.


Referring also to FIG. 7 (which shows the frame alone for purposes of illustration), frame 12 is an annular, stent-like structure having a plurality of angularly spaced, vertically extending, commissure attachment posts, or struts, 18. Posts 18 can be interconnected via a lower row 36a of circumferentially extending struts 20 and first and second rows upper rows 36b, 36c, respectively, of circumferentially extending struts 22 and 24, respectively. The struts in each row desirably are arranged in a zig-zag or generally saw-tooth like pattern extending in the direction of the circumference of the frame as shown. Adjacent struts in the same row can be interconnected to one another as shown in FIGS. 1 and 5 to form an angle A, which desirably is between about 90 and 110 degrees, with about 100 degrees being a specific example. The selection of angle A between approximately 90 and 110 degrees optimizes the radial strength of frame 12 when expanded yet still permits the frame 12 to be evenly crimped and then expanded in the manner described below.


In the illustrated embodiment, pairs of adjacent circumferential struts in the same row are connected to each other by a respective, generally U-shaped crown structure, or crown portion, 26. Crown structures 26 each include a horizontal portion extending between and connecting the adjacent ends of the struts such that a gap 28 is defined between the adjacent ends and the crown structure connects the adjacent ends at a location offset from the strut's natural point of intersection. Crown structures 26 significantly reduce residual strains on the frame 12 at the location of struts 20, 22, 24 during crimping and expanding of the frame 20 in the manner described below. Each pair of struts 22 connected at a common crown structure 26 forms a cell with an adjacent pair of struts 24 in the row above. Each cell can be connected to an adjacent cell at a node 32. Each node 32 can be interconnected with the lower row of struts by a respective vertical (axial) strut 30 that is connected to and extends between a respective node 32 and a location on the lower row of struts 20 where two struts are connected at their ends opposite crown structures 26.


In certain embodiments, lower struts 20 have a greater thickness or diameter than upper struts 22, 24. In one implementation, for example, lower struts 20 have a thickness T (FIG. 9) of about 0.42 mm and upper struts 22, 24 have a thickness T of about 0.38 mm. Because there is only one row of lower struts 20 and two rows of upper struts 22, 24 in the illustrated configuration, enlargement of lower struts 20 with respect to upper struts 22, 24 enhances the radial strength of the frame at the lower area of the frame and allows for more uniform expansion of the frame.



FIG. 9 shows a flattened view of a 120-degree segment of frame 12 shown in FIG. 7, the segment comprising a portion of the frame extending between two posts 18. As shown, the frame segment has three columns 34 and three rows 36a, 36b, 36c of struts per segment. Each column 34 is defined by the adjoining pairs of struts 20, 22, 24 extending between two axially extending struts 18, 30. Frame 12 desirably is comprised of three 120-degree segments, with each segment being bounded by two posts 18. Accordingly, frame 12 in the illustrated embodiment includes 9 total columns per frame.


The number of columns and rows desirably is minimized to reduce the overall crimp profile of the valve, as further discussed below. The arrangement of FIGS. 7 and 9 typically is used for valves that are less than about 29 mm in diameter, and are most suitable for valves that are about 20-26 mm in diameter. In working examples of valves comprising frame 12, a 20-mm valve can be crimped to a diameter of about 17 Fr, a 23-mm valve can be crimped to a diameter of about 18 Fr and a 26-mm valve can be crimped to a diameter of about 19 Fr. For valves that are about 29 mm and larger in diameter, it may be desirable to add another row and column of struts.


For example, FIGS. 8 and 10 show an alternative frame 40 that is similar to frame 12 except that frame 40 has four rows of struts (a lowermost, first row 52a of struts 42, a second row 52b of struts 44, a third row 52c of struts 46, and an uppermost row 52d of struts 48) instead of three rows of struts, as well as four columns 50 of struts for each 120-degree frame segment instead of three columns of struts. FIG. 10 shows a flattened view of a 120-degree segment of frame 40 shown in FIG. 8. Frame 40 in the illustrated embodiment includes three such 120-degree segments, providing 12 total columns 50 of struts for the frame.


Struts 46 of the third row desirably are facing in the opposite direction of the struts 48 of the fourth row (i.e., the apexes or crown portions are facing in the opposite direction), to help avoid buckling of the vertical posts of the frame during crimping and expansion of the valve. Struts 44 of the second row can be arranged so as to be facing in the same direction as the struts 42 of the first row as shown (i.e., the apexes or crown portions are facing in the same direction). Alternatively, struts 44 of the second row can be facing in the opposing direction from struts 42 of the first row so as to form square cells, like the cells formed by the struts 46, 48 of the third and fourth rows, respectively. Frame 40 can also include axially extending struts 54 connected to and extending between the ends of each strut 42, 44, 46, and 48 aligned in a column 50 that are not connected to a post 18. As noted above, frame 40 is most suitable for valves 29 mm and larger in diameter (when expanded to its functional size). In a working example of a valve incorporating frame 40, a 29-mm valve can be crimped to a diameter of about 21 Fr.


Suitable plastically-expandable materials that can be used to form the frame include, without limitation, stainless steel, a nickel based alloy (e.g., a nickel-cobalt-chromium alloy), polymers, or combinations thereof. In particular embodiments, frame 20 is made of a nickel-cobalt-chromium-molybdenum alloy, such as MP35N™ (tradename of SPS Technologies), which is equivalent to UNS R30035 (covered by ASTM F562-02). MP35N™/UNS R30035 comprises 35% nickel, 35% cobalt, 20% chromium, and 10% molybdenum, by weight. It has been found that the use of MP35N to form frame 20 provides superior structural results over stainless steel. In particular, when MP35N is used as the frame material, less material is needed to achieve the same or better performance in radial and crush force resistance, fatigue resistances, and corrosion resistance. Moreover, since less material is required, the crimped profile of the frame can be reduced, thereby providing a lower profile valve assembly for percutaneous delivery to the treatment location in the body.


Referring again to FIG. 1, skirt 16 can be formed, for example, of polyethylene terephthalate (PET) ribbon. The thickness of the skirt can vary, but is desirably less than 6 mil, and desirably less than 4 mil, and even more desirably about 2 mil. Skirt 16 can be secured to the inside of frame 12 via Lenzing sutures 56, as shown in FIG. 1. Leaflet structure 14 can be attached to the skirt via a thin PET reinforcing strip 68 (or sleeve), discussed below, which enables a secure suturing and protects the pericardial tissue of the leaflet structure from tears. Leaflet structure 14 can be sandwiched between skirt 16 and the thin PET strip 68 as shown. Suture 58, which secures the PET strip and the leaflet structure 14 to skirt 16 can be any suitable suture, such as an Ethibond suture. Suture 58 desirably tracks the curvature of the bottom edge of leaflet structure 14, as described in more detail below. Leaflet structure 14 can be formed of bovine pericardial tissue, biocompatible synthetic materials, or various other suitable natural or synthetic materials as known in the art and described in U.S. Pat. No. 6,730,118, which is incorporated by reference herein.


Leaflet structure 14 can comprise three leaflets 60, which can be arranged to collapse in a tricuspid arrangement, as best shown in FIGS. 2 and 6. The lower edge of leaflet structure 14 desirably has an undulating, curved scalloped shape (suture line 58 shown in FIG. 1 tracks the scalloped shape of the leaflet structure). By forming the leaflets with this scalloped geometry, stresses on the leaflets are reduced, which in turn improves durability of the valve. Moreover, by virtue of the scalloped shape, folds and ripples at the belly of each leaflet (the central region of each leaflet), which can cause early calcification in those areas, can be eliminated or at least minimized. The scalloped geometry also reduces the amount of tissue material used to form leaflet structure, thereby allowing a smaller, more even crimped profile at the inflow end of the valve.


Leaflets 60 can be secured to one another at their adjacent sides to form commissures 84 of the leaflet structure (the edges where the leaflets come together). Leaflet structure 14 can be secured to frame 12 using suitable techniques and mechanisms. For example, as best shown in FIG. 6, commissures 84 of the leaflet structure desirably are aligned with the support posts 18 and secured thereto using sutures. The point of attachment of the leaflets to the posts 18 can be reinforced with bars 62 (FIG. 11), which desirably are made of a relatively rigid material (compared to the leaflets), such as stainless steel.



FIG. 13 shows a single leaflet 60, which has a curved lower edge 64 and two flaps 66 extending between the upper edge and curved lower edge of the leaflet. The curved lower edge 64 forms a single scallop. When secured to two other leaflets to form leaflet structure 14, the curved lower edges of the leaflets collectively form the scalloped shaped lower edge portion of the leaflet structure (as best shown in FIG. 18). As further shown in FIG. 13, two reinforcing bars 62 can be secured to the leaflet adjacent to flaps 66 (e.g., using sutures). The flaps can then be folded over bars 62 and secured in the folded position using sutures. If desired, as shown in FIG. 12, each bar 62 can be placed in a protective sleeve 68 (e.g., a PET sleeve) before being secured to a leaflet.


As shown in FIG. 14, the lower curved edge 64 of the leaflet can be reinforced for later securement to the skirt 16, such as by securing a reinforcing strip 68 along the curved lower edge between flaps 66 on the side of the leaflet opposite bars 62. Three such leaflets 60 can be prepared in the same manner and then connected to each other at their flaps 66 in a tricuspid arrangement to form leaflet structure 14, as shown in FIG. 15. The reinforcing strips 68 on the leaflets collectively define a ribbon or sleeve that extends along the lower edge portion of the inside surface of the leaflet structure.


As noted above, leaflet structure 14 can be secured to frame 12 with skirt 16. Skirt 16 desirably comprises a tough, tear resistant material such as PET, although various other synthetic or natural materials can be used. Skirt 16 can be much thinner than traditional skirts. In one embodiment, for example, skirt 16 is a PET skirt having a thickness of about 0.07 mm at its edges and about 0.06 mm at its center. The thinner skirt can provide for better crimping performances while still providing good perivalvular sealing.



FIG. 16 shows a flattened view of the skirt before the opposite ends are secured to each other to form the annular shape shown in FIG. 17. As shown, the upper edge of skirt 16 desirably has an undulated shape that generally follows the shape of the second row of struts 22 of the frame. In this manner, the upper edge of skirt 16 can be tightly secured to struts 22 with sutures 56 (as best shown in FIG. 1). Skirt 16 can also be formed with slits 70 to facilitate attachment of the skirt to the frame. Slits 70 are aligned with crown structures 26 of struts 22 when the skirt is secured to the frame. Slits 70 are dimensioned so as to allow an upper edge portion of skirt to be partially wrapped around struts 22 and reduce stresses in the skirt during the attachment procedure. For example, in the illustrated embodiment, skirt 16 is placed on the inside of frame 12 and an upper edge portion of the skirt is wrapped around the upper surfaces of struts 22 and secured in place with sutures 56. Wrapping the upper edge portion of the skirt around struts 22 in this manner provides for a stronger and more durable attachment of the skirt to the frame. Although not shown, the lower edge of the skirt can be shaped to conform generally to the contour of the lowermost row of struts 22 to improve the flow of blood past the inflow end of the valve.


As further shown in FIG. 17, various suture lines can be added to the skirt to facilitate attachment of the skirt to the leaflet structure and to the frame. For example, a scalloped shaped suture line 72 can be used as a guide to suture the lower edge of the leaflet structure at the proper location against the inner surface of the skirt using suture 59 (as best shown in FIG. 5). Another scalloped shaped suture line 74 (FIG. 17) can be use as a guide to suture the leaflet structure to the skirt using sutures 58 (FIG. 1). Reinforcing strips 68 secured to the lower edge of the leaflets reinforces the leaflets along suture line 58 and protects against tearing of the leaflets. FIG. 18 shows a leaflet assembly comprised of skirt 16 and leaflet structure 14 secured to the skirt. The leaflet assembly can then be secured to frame 12 in the manner described below. In alternative embodiments, the skirt, without the leaflet structure, can be connected to the frame first, and then the leaflet structure can be connected to the skirt.



FIG. 6 shows a top view of the valve assembly attached to frame 12. Leaflets 60 are shown in a generally closed position. As shown, the commissures of the leaflets are aligned with posts 18 of the frame. The leaflets can be secured to the frame using sutures extending through flaps 66 of the leaflets, openings 76 in bars 62, and openings 78 in posts 18, effectively securing flaps 66 to posts 18. As noted above, bars 62 reinforce the flaps at the area of connection with posts and protect against tearing of the leaflets.


As shown in FIG. 6A, bars 62 desirably are aligned perpendicular and as straight as possible with respect to posts 18 of the frame, such that bars 62 and post 18 at each commissure form a “T” shape. The width of bars 62 and the attachment of the commissures via the bars provides a clearance between the deflectable portions of the leaflets 60 (the portions not secured by sutures to the frame) and the frame, while the edge radius (thickness) of bars 62 serves as a flex hinge for the leaflets 60 during valve opening and closing, thereby increasing the space between the leaflets and the frame. By increasing the space between the moving portions of the leaflets and frame and by having the leaflets flex against an edge radius of bars 62, contact between the moving portions of the leaflets (especially the outflow edges of the leaflets) and the frame can be avoided during working cycles, which in turn improves the durability of the valve assembly. This configuration also enhances perfusion through the coronary sinuses.



FIG. 19 depicts a side view of a valve 10 crimped on a balloon delivery catheter 100. The valve is crimped onto balloon 110 of balloon catheter 100. It is desirable to protect leaflet structure 14 of the valve from damage during crimping to ensure durability of the leaflet structure and at the same time, it is desirable to reduce as much as possible the crimped profile size of the valve. During the crimping procedure the tissue of the leaflet structure (e.g., bovine pericardial tissue or other suitable tissue) is pressed against the inner surface of the metal frame and portions of the tissue can protrude into the open cells of the frame between the struts and can be pinched due to the scissor-like motion of the struts of the frame. If the valve is severely crimped to achieve a small crimping size, this scissor-like motion can result in cuts and rupture of the tissue leaflets.


Skirt 16, described above, can protect against damage to the leaflet structure during crimping to a certain degree. However, the skirt's main purpose is structural and it does not in certain embodiments cover the entire frame. Therefore, in such embodiments, the skirt may not fully protect the leaflet structure during crimping and as such, the frame can still cause damage to the leaflet structure.



FIGS. 20 and 21 show an embodiment of a crimping apparatus for atraumatic crimping of a valve onto a balloon in a manner that further protects against damage to the leaflets. The crimping apparatus (also referred to as a crimper), indicated generally at 200, has an aperture 202 sized to receive a valve in an expanded state. FIG. 20 shows aperture 202 in a fully open or dilated state with a valve 10 positioned inside aperture 202. Crimping apparatus 200 has a plurality of crimper jaws 206 (12 in the illustrated embodiment) which are configured to move radially inwardly to radially compress (crimp) the valve to a smaller profile around the balloon of a balloon catheter.


A deformable material is positioned between the outside of the frame and the crimping jaws 206. In the illustrated embodiment, the deformable material comprises a protective sleeve, or covering, 204 that is placed around the valve so that it covers the outer surface of the frame of the valve and prevents the hard surface of the crimping jaws from directly contacting the frame of the valve. The sleeve 204 desirably is sized to fully cover the outer surface of the frame. Sleeve 204 desirably is made of a soft, flexible and compressible material. The sleeve can be formed from generally available materials, including, but not limited to, natural or synthetic sponge (e.g., polyurethane sponge), a foamed material made of a suitable polymer such as polyurethane or polyethylene, or any of various suitable elastomeric materials, such as polyurethane, silicon, polyolefins or a variety of hydrogels, to name a few.


The sleeve is desirably stored in a wet environment (e.g., immersed in saline) prior to use. After placing sleeve 204 around the valve, the valve and the sleeve are placed into crimping apparatus 200 as shown in FIG. 20. Balloon 110 of a balloon catheter can then be positioned within the leaflets 60 of the valve (FIG. 21). FIG. 21 shows crimper jaws 206 surrounding sleeve 204, which in turn surrounds frame 12 and leaflet structure 14 of valve 10. Balloon 110 typically is placed at the center of the valve so that the valve can be evenly expanded during implantation of the valve within the body.


As seen in FIG. 21, during crimping, the sponge-like material of protective sleeve 204 protrudes into the open cells of frame 12 and occupies this space, thereby preventing leaflet structure 14 from entering this space and being pinched or otherwise damaged. After crimping is completed, the valve with the protective sleeve is removed from the crimping apparatus. Sleeve 204 can then be gently peeled away from the frame. Because the protective sleeve presses the leaflet structure inwardly and away from the frame during crimping, the valve can be crimped to a small profile without damaging the leaflet structure.



FIGS. 23 and 24 illustrate an advantage that can be gained by using protective sleeve 204. FIG. 23 shows a prosthetic valve that was crimped without using the protective sleeve. Dotted line 300 identifies an area of the valve where leaflet structure 302 has been pressed between struts of a frame 304, which can damage the leaflet structure as discussed above.


In contrast, FIG. 24 shows a prosthetic valve that was crimped using protective sleeve 204. In this example, leaflet structure 302 was pressed inwardly and away from the inside of frame 304 and, therefore, the leaflet structure was not pinched or squeezed between the struts of the frame.


Accordingly, since the leaflet structure is pushed away from the frame when the protective sleeve is used, the leaflet structure is less likely to be pinched or cut during the crimping process. Also, when using a protective sleeve, a very ordered structure of balloon-leaflets-frame (from inward to outward) can be achieved. When no such protective sleeve is utilized, some portion of the balloon, leaflets, and frame are much more likely to overlap after the crimping procedure and the resulting structure is less predictable and uniform.


In addition to the foam or sponge-type protective sleeve described above, other types of sleeves or protective layers of deformable material can be used to protect the leaflets against damage during crimping of a valve. In one implementation, for example, a layer (e.g., rectangular slices) of deformable material (e.g., sponge, rubber, silicon, polyurethane, etc.) can be disposed on each crimping jaw 206 so as to form a sleeve around the valve upon crimping. Alternatively, deformable packets filled with a flowable, deformable material, such as a gel or gas, can be disposed on each crimping jaw for contacting the valve upon crimping. In addition, the deformable material (e.g., sleeve 204) can be covered with a thin PET cloth, among many other fabric materials or other suitable materials, to prevent particles of the deformable materials from migrating to the valve during crimping.


The skirt of a prosthetic valve serves several functions. In particular embodiments, for example, the skirt functions to seal and prevent (or decrease) perivalvular leakage, to anchor the leaflet structure to the frame, and to protect the leaflets against damage caused by contact with the frame during crimping and during working cycles of the valve. The skirt used with the prosthetic valve discussed above has been described as being a fabric, such as a PET cloth. PET or other fabrics are substantially non-elastic (i.e., substantially non-stretchable and non-compressible). As such, the skirt in certain implementations limits the smallest achievable crimping diameter of the valve and can wrinkle after expansion from the crimped diameter.


In alternative embodiments, such as discussed below, a prosthetic valve can be provided with a skirt that is made of a stretchable and/or compressible material, such as silicon. Due to the compressibility of such a skirt, the valve can be crimped to a relatively smaller diameter as compared to a valve having a non-compressible skirt. Furthermore, such a skirt can recover its original, smooth surfaces with little or no wrinkling after expansion from the crimped state.



FIG. 25 shows an embodiment of a frame 12 that has an elastic “over-tube” skirt or sleeve 340 that extends completely around and covers at least a portion of the outside of the frame. In particular embodiments, skirt 340 is made of silicon, which can undergo large deformations while maintaining its elasticity. Such a silicon skirt can be a thin sleeve that covers a portion of frame 12 from the outside. In the illustrated embodiment, the height of the skirt is less than the overall height of frame 12, however, the skirt can vary in height and need not be the height shown in FIG. 25. For example, the height of the skirt can be the same as or greater than that of the frame so as to completely cover the outside of the frame. In an alternative embodiment, the skirt 340 can be mounted to the inside of the frame using, for example, sutures or an adhesive. When mounted inside of the frame, the skirt can protect the leaflets from abrasion against the inside of the frame. Other materials that can be used to form the skirt or sleeve include, but are not limited to, PTFE, ePTFE, polyurethane, polyolefins, hydrogels, biological materials (e.g., pericardium or biological polymers such as collagen, gelatin, or hyaluronic acid derivatives) or combinations thereof.


In another embodiment, the entire frame or a portion thereof can be dipped in liquefied material (e.g., liquid silicon or any of the materials described above for forming the sleeve 340 that can be liquefied for dip coating the frame) in order to encapsulate the entire frame (or at least that portion that is dipped) in silicon. FIG. 26 is a side view of a frame 12 that has been dipped in silicon to form a continuous cylindrical silicon covering 342 encapsulating the struts of the frame and filling the spaces between the struts. FIG. 26 shows the covering 342 before it is trimmed to remove excess material extending beyond the ends of the frame. Although less desirable, the frame can be dipped such that the silicon encapsulates the struts of the frame but does not fill the open spaces between the struts of the frame.



FIG. 27 shows an embodiment of a prosthetic valve 400 comprising a frame 402 and a leaflet structure 404 mounted to the inside of the frame (e.g., using sutures as shown). Frame 402 has a skirt in the form of silicon covering 406 that is formed, for example, by dipping the frame into liquid silicon. FIG. 27 shows valve 400 in its expanded state. In FIG. 28, valve 400 has been crimped to a smaller profile. During crimping, coating 406, which extends across and fills the open cells between the struts of the frame, is effective to push leaflet structure 404 inward and away from the frame, thereby protecting the leaflet structure from pinching or tearing. FIG. 29 shows valve 400 after being expanded by a balloon of a balloon catheter.


In order to test the durability and stretch resistance of the silicon used, several uniaxial tests were conducted. In particular, silicon strips of about 5×50 mm (with a thickness of about 0.85 mm) were tested in a uniaxial tester. FIGS. 30A-30C show graphs of the results of the uniaxial testing of silicon strips. In addition, tears were deliberately introduced into silicon strips at a middle of the strips and at the edge of the strips while the strips were stretched on a uniaxial tester. The tears were introduced by making holes in the silicon strips with a needle. FIGS. 31A-31F show graphs of the results of the uniaxial testing of silicon strips with deliberately introduced tears.


It was found that ultimate tensile stretch for a thin layer of silicon was over 500% and that samples that had tears that were deliberately introduced continued to show notable strength. Accordingly, the elasticity of silicon permits silicon dipped frames to be crimped to very low profiles and expanded back out to larger profiles without significant damage to the silicon layer. In addition, the silicon material can increase friction between the frame and the native annulus where the prosthetic valve is implanted, resulting in better anchoring and preventing/reducing perivalvular leaks.


A silicon skirt can be mounted on a frame by various means, including by using a mandrel. Also, it may be desirable to use a silicon skirt in combination with a cloth or fabric skirt. For example, it may be desirable to place a silicon skirt on the outside of a cloth or fabric skirt that is surrounding at least a portion of a frame.


Alternatively or additionally, a silicon skirt could also be placed on the inside of the frame and attached to the frame so that it offers the leaflets improved protecting during working cycles. Alternatively, instead of silicon, the skirt can be made of an auxetic and/or swelling material, such as synthetic or natural hydrogels. An auxetic material is one that expands laterally while stretched longitudinally, which means that this material has a negative Poisson ration. If the frame is covered with an auxetic material it can expand radially while being stretched circumferentially when the valve is expanded from its crimped state. Such expansion can improve the fit of the valve at the native valve annulus, thereby preventing or reducing perivalvular leakage.


In view of the many possible embodiments to which the principles of the disclosed invention may be applied, it should be recognized that the illustrated embodiments are only preferred examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.

Claims
  • 1. A prosthetic heart valve comprising: a radially collapsible and expandable annular frame, the frame having at least three circumferentially extending rows of angled struts arranged in a zig-zag pattern in each row, the at least three rows including a first row of angled struts defining an inflow end of the frame, a second row of angled struts defining an outflow end of the frame, a third row of angled struts positioned axially between the first and second rows of angled struts along a length of the frame;wherein the frame comprises a circumferentially extending, upper row of closed cells defined between the second and third rows of angled struts, the cells defining openings in the frame;wherein the frame comprises three commissure attachment posts;a leaflet structure comprising three separate leaflets, wherein each leaflet comprises pericardial tissue, each leaflet having an upper edge portion, a curved lower edge portion and two side flaps, wherein each side flap has a height that is less than an overall height of the leaflet in a flattened state of the leaflet prior to assembly of the leaflet structure, wherein the curved lower edge portion extends from the lower end of one of the side flaps to the lower end of the other side flap, and wherein each side flap is connected to an adjacent side flap of another leaflet to form commissures of the leaflet structure, each commissure being attached to the frame;wherein each commissure is connected to one of the commissure attachment posts with sutures extending through apertures in the commissure attachment posts only at locations along the commissure attachment posts between the outflow end of the frame and an upstream end of the upper row of closed cells;an annular inner sleeve comprising three U-shaped portions positioned along the curved lower edge portions of the leaflets, wherein the inner sleeve is a separate piece of material from the leaflets and wherein each leaflet is sutured to the inner sleeve along the curved lower edge portion; andan annular outer sleeve extending around an outer surface of the frame, wherein the outer sleeve is made of pericardium.
  • 2. The prosthetic heart valve of claim 1, wherein the outer sleeve has a height that is less than a height of the frame.
  • 3. The prosthetic heart valve of claim 2, wherein an inflow end portion of the outer sleeve covers the struts of the first row of struts.
  • 4. The prosthetic heart valve of claim 1, wherein the commissures of the leaflet structure are attached to the frame with sutures.
  • 5. The prosthetic heart valve of claim 4, wherein the zig-zag pattern of the second row of angled struts is opposite from the first and third rows.
  • 6. The prosthetic heart valve of claim 1, wherein the first and third rows of angled struts have parallel zig-zag patterns.
  • 7. The prosthetic heart valve of claim 1, wherein the first row of angled struts define a plurality of U-shaped crown structures that interconnect adjacent ends of two angled struts at the inflow end of the frame and the second row of angled struts define a plurality of U-shaped crown structures that interconnect adjacent ends of two angled struts at the outflow end of the frame.
  • 8. The prosthetic heart valve of claim 7, wherein the first row of angled struts forms exactly twelve crown structures at the inflow end of the frame.
  • 9. The prosthetic heart valve of claim 1, wherein the commissure attachment posts have cantilevered ends adjacent the outflow end of the frame.
  • 10. A prosthetic heart valve comprising: a radially collapsible and expandable annular frame, the frame having at least three circumferentially extending rows of angled struts arranged in a zig-zag pattern in each row, the at least three rows including a first row of angled struts defining an inflow end of the frame, a second row of angled struts defining an outflow end of the frame, a third row of angled struts positioned axially between the first and second rows of angled struts along a length of the frame, wherein the frame comprises a plurality of circumferentially extending rows of closed cells defined between adjacent rows of angled struts, including an upper row of closed cells defined between the second and third row of angled struts;wherein the frame comprises three commissure attachment posts;a leaflet structure comprising three separate leaflets, wherein each leaflet comprises pericardial tissue, each leaflet having an upper edge portion, a curved lower edge portion and two side flaps, wherein each side flap has a height that is less than an overall height of the leaflet in a flattened state of the leaflet prior to assembly of the leaflet structure, wherein the curved lower edge portion extends from the lower end of one of the side flaps to the lower end of the other side flap, and wherein each side flap is connected to an adjacent side flap of another leaflet to form commissures of the leaflet structure, each commissure being attached to the frame;wherein each commissure is connected to one of the commissure attachment posts only at locations along the commissure attachment posts between the outflow end of the frame an upstream end of the upper row of closed cells;an annular inner skirt member positioned against an inner surface of the frame, wherein the inner skirt member is a separate piece of material from the leaflets and wherein each leaflet is sutured to the inner skirt member along the curved lower edge portion; andan annular outer sleeve extending around an outer surface of the frame wherein the outer sleeve is made of pericardium;wherein the inner skirt member and the outer sleeve are separate pieces of material.
  • 11. The prosthetic heart valve of claim 10, wherein the inner skirt has a lower edge portion that is sutured to struts of the first row of angled struts.
  • 12. The prosthetic heart valve of claim 11, wherein the lower edge portion of the inner skirt extends below the lower edge portions of the leaflets in a direction toward the inflow end of the frame.
  • 13. The prosthetic heart valve of claim 10, wherein the outer sleeve has a lower edge portion that covers the struts of the first row of angled struts.
  • 14. The prosthetic heart valve of claim 13, wherein the outer sleeve covers two rows of closed cells closest to the inflow end of the frame.
  • 15. The prosthetic heart valve of claim 14, wherein the outer sleeve has a height that is less than a height of the frame.
  • 16. The prosthetic heart valve of claim 10, wherein the commissures of the leaflet structure are attached to the frame with sutures.
  • 17. The prosthetic heart valve of claim 10, wherein the first and third rows of angled struts have parallel zig-zag patterns.
  • 18. The prosthetic heart valve of claim 17, wherein the zig-zag pattern of the second row of angled struts is opposite from the first and third rows.
  • 19. The prosthetic heart valve of claim 10, wherein each commissure is connected to one of the commissure attachment posts with sutures extending through apertures in the commissure attachment posts only at locations downstream of the upstream end of the upper row of closed cells.
  • 20. The prosthetic heart valve of claim 19, wherein the sutures extend through the commissures and the apertures in the commissure attachment posts.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/570,780, filed Sep. 13, 2019, which is a continuation of U.S. patent application Ser. No. 16/202,980, filed Nov. 28, 2018, now U.S. Pat. No. 10,426,611, which is a continuation of U.S. patent application Ser. No. 15/984,716, filed May 21, 2018, now U.S. Pat. No. 10,492,905, which is a continuation of U.S. patent application Ser. No. 15/599,802, filed May 19, 2017, now U.S. Pat. No. 9,974,652, which is a divisional of U.S. patent application Ser. No. 14/483,862, filed Sep. 11, 2014, now U.S. Pat. No. 9,662,204, which is a continuation of U.S. patent application Ser. No. 13/897,036, filed May 17, 2013, now abandoned, which is a continuation of U.S. patent application Ser. No. 13/167,549, filed Jun. 23, 2011, now U.S. Pat. No. 8,454,685, which is a continuation of U.S. patent application Ser. No. 12/480,603, filed Jun. 8, 2009, now U.S. Pat. No. 7,993,394, which claims the benefit of U.S. Patent Application No. 61/059,656, filed Jun. 6, 2008, the entire disclosures of which are incorporated herein by reference.

US Referenced Citations (389)
Number Name Date Kind
3409013 Berry Nov 1968 A
3534411 Shiley Oct 1970 A
3548417 Kisher Dec 1970 A
3551913 Shiley et al. Jan 1971 A
3570014 Hancock Mar 1971 A
3587115 Shiley Jun 1971 A
3608097 Bellhouse Sep 1971 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3755823 Hancock Sep 1973 A
3818511 Goldberg et al. Jun 1974 A
3848578 Bucalo Nov 1974 A
3983581 Angell et al. Oct 1976 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4084268 Ionescu et al. Apr 1978 A
4106129 Carpentier et al. Aug 1978 A
4173606 Stoy et al. Nov 1979 A
4192020 Davis et al. Mar 1980 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos et al. May 1981 A
4297749 Davis et al. Nov 1981 A
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4373216 Klawitter Feb 1983 A
4406022 Roy Sep 1983 A
4441216 Ionescu et al. Apr 1984 A
4470157 Love Sep 1984 A
4477930 Totten et al. Oct 1984 A
4501030 Lane Feb 1985 A
4506394 Bedard Mar 1985 A
4535483 Klawitter et al. Aug 1985 A
4574803 Storz Mar 1986 A
4592340 Boyles Jun 1986 A
4605407 Black et al. Aug 1986 A
4612011 Kautzky Sep 1986 A
4643732 Pietsch et al. Feb 1987 A
4655771 Wallsten Apr 1987 A
4662890 Burton May 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4733665 Palmaz Mar 1988 A
4759758 Gabbay Jul 1988 A
4762128 Rosenbluth Aug 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4820299 Philippe et al. Apr 1989 A
4829990 Thuroff et al. May 1989 A
4851001 Taheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4922905 Strecker May 1990 A
4966604 Reiss Oct 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5059177 Towne et al. Oct 1991 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5139515 Robicsek Aug 1992 A
5147399 Dellon et al. Sep 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5192297 Hull Mar 1993 A
5266073 Wall Nov 1993 A
5282847 Trescony et al. Feb 1994 A
5295958 Shturman Mar 1994 A
5332402 Teitelbaum Jul 1994 A
5360444 Kusuhara Nov 1994 A
5370685 Stevens Dec 1994 A
5397351 Pavcnik et al. Mar 1995 A
5411055 Kane May 1995 A
5411552 Andersen et al. May 1995 A
5425739 Jessen Jun 1995 A
5443446 Shturman Aug 1995 A
5469868 Reger Nov 1995 A
5476506 Lunn Dec 1995 A
5480424 Cox Jan 1996 A
5489297 Duran Feb 1996 A
5500014 Quijano et al. Mar 1996 A
5522881 Lentz Jun 1996 A
5545209 Roberts et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554185 Block et al. Sep 1996 A
5558644 Boyd et al. Sep 1996 A
5562727 Turk et al. Oct 1996 A
5571175 Vanney et al. Nov 1996 A
5584803 Stevens et al. Dec 1996 A
5591185 Kilmer et al. Jan 1997 A
5591195 Taheri et al. Jan 1997 A
5607464 Trescony et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5628784 Strecker May 1997 A
5628792 Lentell May 1997 A
5639274 Fischell et al. Jun 1997 A
5665115 Cragg Sep 1997 A
5665117 Rhodes Sep 1997 A
5681345 Euteneuer Oct 1997 A
5713953 Vallana et al. Feb 1998 A
5716417 Girard et al. Feb 1998 A
5728068 Leone et al. Mar 1998 A
5741324 Glastra Apr 1998 A
5741331 Pinchuk Apr 1998 A
5749890 Shaknovich May 1998 A
5756476 Epstein et al. May 1998 A
5769812 Stevens et al. Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5800508 Goicoechea et al. Sep 1998 A
5840081 Andersen et al. Nov 1998 A
5843158 Lenker et al. Dec 1998 A
5843160 Rhodes Dec 1998 A
5853419 Imran Dec 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5891195 Klostermeyer et al. Apr 1999 A
5910170 Reimink et al. Jun 1999 A
5925063 Khosravi Jul 1999 A
5944750 Tanner et al. Aug 1999 A
5948191 Solovay Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
6010529 Herweck et al. Jan 2000 A
6015431 Thornton et al. Jan 2000 A
6027525 Suh et al. Feb 2000 A
6056762 Nash et al. May 2000 A
6096071 Yadav Aug 2000 A
6132473 Williams et al. Oct 2000 A
6159656 Kawabe et al. Dec 2000 A
6168614 Andersen et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6174327 Mertens et al. Jan 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6217585 Houser et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6231602 Carpentier et al. May 2001 B1
6245102 Jayaraman Jun 2001 B1
6254636 Peredo Jul 2001 B1
6258120 McKenzie et al. Jul 2001 B1
6273917 Inoue Aug 2001 B1
6287335 Drasler et al. Sep 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6299638 Sauter Oct 2001 B1
6302906 Goecoechea et al. Oct 2001 B1
6306163 Fitz Oct 2001 B1
6309417 Spence et al. Oct 2001 B1
6331188 Lau et al. Dec 2001 B1
6350277 Kocur Feb 2002 B1
6371983 Lane Apr 2002 B1
6395019 Chobotov May 2002 B2
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6458156 Wan et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6482228 Norred Nov 2002 B1
6488704 Connelly et al. Dec 2002 B1
6494909 Greenhalgh Dec 2002 B2
6503272 Duerig et al. Jan 2003 B2
6527979 Constantz Mar 2003 B2
6551350 Thornton et al. Apr 2003 B1
6569196 Vesely May 2003 B1
6582462 Andersen et al. Jun 2003 B1
6585761 Taheri Jul 2003 B2
6605112 Moll et al. Aug 2003 B1
6652578 Bailey et al. Nov 2003 B2
6673285 Ma Jan 2004 B2
6716244 Klaco Apr 2004 B2
6719781 Kim Apr 2004 B1
6730118 Spenser et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6767362 Schreck Jul 2004 B2
6773456 Gordon et al. Aug 2004 B1
6830584 Seguin Dec 2004 B1
6878162 Bales et al. Apr 2005 B2
6893460 Spenser May 2005 B2
6896690 Lambrecht et al. May 2005 B1
6908481 Cribier Jun 2005 B2
6918926 Letort Jul 2005 B2
6936067 Buchanan Aug 2005 B2
7018406 Seguin et al. Mar 2006 B2
7018408 Bailey et al. Mar 2006 B2
7044962 Elliott May 2006 B2
7083648 Yu et al. Aug 2006 B2
7090693 Chobotov et al. Aug 2006 B1
7220274 Quinn May 2007 B1
7273493 Ledergerber Sep 2007 B2
7276078 Spenser et al. Oct 2007 B2
7276084 Yang et al. Oct 2007 B2
7318278 Zhang et al. Jan 2008 B2
7329279 Haug et al. Feb 2008 B2
7374571 Pease et al. May 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7393360 Spenser et al. Jul 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7462191 Spenser et al. Dec 2008 B2
7510571 Spiridigliozzi et al. Mar 2009 B2
7510575 Spenser et al. Mar 2009 B2
7563277 Case et al. Jul 2009 B2
7563280 Anderson et al. Jul 2009 B2
7585321 Cribier Sep 2009 B2
7615373 Simpson et al. Nov 2009 B2
7618446 Andersen et al. Nov 2009 B2
7618447 Case et al. Nov 2009 B2
7655034 Mitchell et al. Feb 2010 B2
7704740 Schindler et al. Apr 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7780725 Haug et al. Aug 2010 B2
7785366 Maurer et al. Aug 2010 B2
7824442 Salahieh et al. Nov 2010 B2
7824443 Salahieh et al. Nov 2010 B2
7862609 Butaric et al. Jan 2011 B2
7959666 Salahieh et al. Jun 2011 B2
7959672 Salahieh et al. Jun 2011 B2
7988724 Salahieh et al. Aug 2011 B2
7993386 Elliott Aug 2011 B2
7993394 Hariton Aug 2011 B2
8029556 Rowe Oct 2011 B2
8048153 Salahieh et al. Nov 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8167932 Bourang May 2012 B2
8182528 Salahieh et al. May 2012 B2
8231670 Salahieh et al. Jul 2012 B2
8246678 Salahieh et al. Aug 2012 B2
8252052 Salahieh et al. Aug 2012 B2
8287584 Salahieh et al. Oct 2012 B2
8291570 Eidenschink et al. Oct 2012 B2
8328868 Paul et al. Dec 2012 B2
8343213 Salahieh et al. Jan 2013 B2
8449606 Eliasen et al. May 2013 B2
8454685 Hariton Jun 2013 B2
8579962 Salahieh et al. Nov 2013 B2
8603160 Salahieh et al. Dec 2013 B2
8617236 Paul et al. Dec 2013 B2
8623076 Salahieh et al. Jan 2014 B2
8623078 Salahieh et al. Jan 2014 B2
8668733 Haug et al. Mar 2014 B2
8740974 Lambrecht et al. Jun 2014 B2
8747463 Fogarty et al. Jun 2014 B2
8828078 Salahieh et al. Sep 2014 B2
8840662 Salahieh et al. Sep 2014 B2
8840663 Salahieh et al. Sep 2014 B2
8858620 Salahieh et al. Oct 2014 B2
8894703 Salahieh et al. Nov 2014 B2
8951299 Paul et al. Feb 2015 B2
8961599 Bruchman et al. Feb 2015 B2
8992608 Haug et al. Mar 2015 B2
9005273 Salahieh et al. Apr 2015 B2
9011521 Haug et al. Apr 2015 B2
9119716 Lee et al. Sep 2015 B2
9277991 Salahieh et al. Mar 2016 B2
9308085 Salahieh et al. Apr 2016 B2
9320599 Salahieh et al. Apr 2016 B2
9393110 Levi et al. Jul 2016 B2
9554900 Bruchman et al. Jan 2017 B2
9662204 Hariton et al. May 2017 B2
9974652 Hariton et al. May 2018 B2
10179047 Lee et al. Jan 2019 B2
10292817 Hariton et al. May 2019 B2
10413407 Hariton Sep 2019 B2
10426611 Tariton et al. Oct 2019 B2
10433958 Levi et al. Oct 2019 B2
10470878 Bruchman et al. Nov 2019 B2
10492905 Hariton et al. Dec 2019 B2
10537423 Levi et al. Jan 2020 B2
10849741 Levi et al. Dec 2020 B2
11213388 Hariton Jan 2022 B2
20010021872 Bailey et al. Sep 2001 A1
20010027338 Greenberg Oct 2001 A1
20010037142 Stelter et al. Nov 2001 A1
20020026094 Roth Feb 2002 A1
20020032481 Gabbay Mar 2002 A1
20020052643 Wholey et al. May 2002 A1
20020058987 Butaric et al. May 2002 A1
20020138135 Duerig et al. Sep 2002 A1
20020173842 Buchanan Nov 2002 A1
20030009211 DiCarlo Jan 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030100939 Yodfat et al. May 2003 A1
20030120331 Chobotov et al. Jun 2003 A1
20030125797 Chobotov et al. Jul 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030158597 Quiachon et al. Aug 2003 A1
20030167089 Lane Sep 2003 A1
20030212450 Schlick Nov 2003 A1
20030212454 Scott et al. Nov 2003 A1
20030216803 Ledergerber Nov 2003 A1
20030236567 Elliot Dec 2003 A1
20040039436 Spenser Feb 2004 A1
20040082989 Cook et al. Apr 2004 A1
20040093060 Seguin et al. May 2004 A1
20040186563 Iobbi Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040260389 Case et al. Dec 2004 A1
20050075728 Nguyen et al. Apr 2005 A1
20050096736 Osse et al. May 2005 A1
20050131518 Hartley et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050159811 Lane Jul 2005 A1
20050188525 Weber et al. Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20060004469 Sokel Jan 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060149350 Patel et al. Jul 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060183383 Asmus et al. Aug 2006 A1
20060195172 Luo et al. Aug 2006 A1
20060224228 Dehdashtian et al. Oct 2006 A1
20060229719 Marquez et al. Oct 2006 A1
20060259136 Nguyen Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060265056 Nguyen et al. Nov 2006 A1
20060287717 Rowe et al. Dec 2006 A1
20070005131 Taylor Jan 2007 A1
20070010877 Salahieh et al. Jan 2007 A1
20070088425 Schaeffer Apr 2007 A1
20070112422 Dehdashtian May 2007 A1
20070162102 Ryan et al. Jul 2007 A1
20070203503 Salahieh et al. Aug 2007 A1
20070203575 Forster et al. Aug 2007 A1
20070203576 Lee et al. Aug 2007 A1
20070208550 Cao Sep 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070260305 Drews et al. Nov 2007 A1
20070265700 Eliasen et al. Nov 2007 A1
20080071361 Tuval et al. Mar 2008 A1
20080114442 Mitchell et al. May 2008 A1
20080125853 Bailey et al. May 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080275537 Limon Nov 2008 A1
20090125118 Gong May 2009 A1
20090157175 Benichou Jun 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090299452 Eidenschink et al. Dec 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20100049313 Alon et al. Feb 2010 A1
20100198347 Zakay et al. Aug 2010 A1
20100204781 Alkhatib Aug 2010 A1
20100249922 Li et al. Sep 2010 A1
20100297768 Schindler et al. Nov 2010 A1
20110015729 Jimenez et al. Jan 2011 A1
20110218620 Meiri et al. Sep 2011 A1
20110250689 Baaijens et al. Oct 2011 A1
20110311746 Ma et al. Dec 2011 A1
20110319991 Hariton et al. Dec 2011 A1
20120061314 Choi et al. Mar 2012 A1
20120123529 Levi et al. May 2012 A1
20120253453 Bruchman et al. Oct 2012 A1
20120296418 Bonyuet et al. Nov 2012 A1
20120323315 Bruchman et al. Dec 2012 A1
20130023985 Khairkhahan et al. Jan 2013 A1
20130268044 Parsons et al. Oct 2013 A1
20130310924 Groothuis et al. Nov 2013 A1
20130310926 Hariton Nov 2013 A1
20130317598 Rowe et al. Nov 2013 A1
20140209238 Bonyuet et al. Jul 2014 A1
20140288642 Yoshida et al. Sep 2014 A1
20150224231 Bruchman et al. Aug 2015 A1
20150257875 Bruchman et al. Sep 2015 A1
20150257876 Bruchman et al. Sep 2015 A1
20150305862 Bruchman et al. Oct 2015 A1
20150306277 Pathak et al. Oct 2015 A1
20150366663 Bruchman et al. Dec 2015 A1
20160067374 Puckett et al. Mar 2016 A1
20160074161 Bennett Mar 2016 A1
20160100939 Armstrong et al. Apr 2016 A1
20160175095 Dienno et al. Jun 2016 A1
20160175096 Dienno et al. Jun 2016 A1
20180263769 Hariton et al. Sep 2018 A1
20190091018 Hariton et al. Mar 2019 A1
20190099268 Hariton et al. Apr 2019 A1
Foreign Referenced Citations (86)
Number Date Country
2246526 Mar 1973 DE
19532846 Mar 1997 DE
19546692 Jun 1997 DE
19857887 Jul 2000 DE
19907646 Aug 2000 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049814 Apr 2002 DE
10049815 Apr 2002 DE
0103546 Mar 1984 EP
0144167 Jun 1985 EP
0597967 May 1994 EP
0592410 Oct 1995 EP
0850607 Jul 1998 EP
1057460 Dec 2000 EP
1088529 Apr 2001 EP
1570809 Sep 2005 EP
1796597 Jun 2007 EP
3476367 May 2019 EP
3501455 Jun 2019 EP
3476367 Dec 2019 EP
3501455 Dec 2019 EP
2788217 Jul 2000 FR
2815844 May 2002 FR
2056023 Mar 1981 GB
1271508 Nov 1986 SU
9117720 Nov 1991 WO
9217118 Oct 1992 WO
9301768 Feb 1993 WO
9724080 Jul 1997 WO
9822159 May 1998 WO
9829057 Jul 1998 WO
9930646 Jun 1999 WO
9933414 Jul 1999 WO
9940964 Aug 1999 WO
9944540 Sep 1999 WO
9947075 Sep 1999 WO
0018333 Apr 2000 WO
0041652 Jul 2000 WO
0047139 Aug 2000 WO
0135878 May 2001 WO
0149213 Jul 2001 WO
0154624 Aug 2001 WO
0154625 Aug 2001 WO
0162189 Aug 2001 WO
0047139 Sep 2001 WO
0164137 Sep 2001 WO
0166035 Sep 2001 WO
0176510 Oct 2001 WO
0222054 Mar 2002 WO
0236048 May 2002 WO
0241789 May 2002 WO
0243620 Jun 2002 WO
0247575 Jun 2002 WO
0249540 Jun 2002 WO
03047468 Jun 2003 WO
2004082527 Sep 2004 WO
2005034812 Apr 2005 WO
2005084595 Sep 2005 WO
2006014233 Feb 2006 WO
2006034008 Mar 2006 WO
2006070372 Jul 2006 WO
2006111391 Oct 2006 WO
2006127089 Nov 2006 WO
2006138173 Dec 2006 WO
2005102015 Apr 2007 WO
2007047488 Apr 2007 WO
2007067942 Jun 2007 WO
2007097983 Aug 2007 WO
2007103229 Sep 2007 WO
2008005405 Jan 2008 WO
2008011261 Jan 2008 WO
2008035337 Mar 2008 WO
2008070244 Jun 2008 WO
2008079962 Jul 2008 WO
2008091515 Jul 2008 WO
2008106531 Sep 2008 WO
2008147964 Dec 2008 WO
2008150529 Dec 2008 WO
2009029199 Mar 2009 WO
2009033469 Mar 2009 WO
2009042196 Apr 2009 WO
2009052188 Apr 2009 WO
2009053497 Apr 2009 WO
2009149462 Dec 2009 WO
2010121076 Oct 2010 WO
Non-Patent Literature Citations (9)
Entry
Andersen, et al., Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results withimplantation by catheter technique in closed chest pigs. European Heart Journal (1992), 13, 704-708.
Andersen, Henning Rud, History of Percutaneous Aortic Valve Prosthesis, Herz 34 2009 Nr. 5, Urban & Vogel, pp. 343-346, Skejby University Hospital Department of Cardiology, Aarhus, Denmark.
Pavcnik, et al. “Development and initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement,” Cardiovascular Radiology, vol. 183, No. 1. pp. 151-154. 1992.
Bailey, S. “Percutaneous Expandable Prosthetic Valves,” Textbook of Interventional Cardiology vol. 2, 2nd Ed. pp. 1268-1276. 1994.
Al-Khaja, et al. “Eleven Years' Experience with Carpentier-Edwards Biological Valves in Relation to Survival and Complications,” European Journal of Cardiothoracic Surgery, vol. 3. pp. 305-311. 1989.
Ross, “Aortic Valve Surgery,” At a meeting of the Council on Aug. 4, 1966. pp. 192-197.
Sabbah, et al. “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview,” Journal of Cardiac Surgery, vol. 4, No. 4. pp. 302-309. 1989.
Wheatley, “Valve Prostheses,” Operative Surgery, 4th ed. pp. 415-424. 1986.
Uchida, “Modifications of Gianturco Expandable Wire Stents,” American Journal of Roentgenology, vol. 150. pp. 1185-1187. 1986.
Related Publications (1)
Number Date Country
20200405482 A1 Dec 2020 US
Provisional Applications (1)
Number Date Country
61059656 Jun 2008 US
Divisions (1)
Number Date Country
Parent 14483862 Sep 2014 US
Child 15599802 US
Continuations (7)
Number Date Country
Parent 16570780 Sep 2019 US
Child 17018258 US
Parent 16202980 Nov 2018 US
Child 16570780 US
Parent 15984716 May 2018 US
Child 16202980 US
Parent 15599802 May 2017 US
Child 15984716 US
Parent 13897036 May 2013 US
Child 14483862 US
Parent 13167549 Jun 2011 US
Child 13897036 US
Parent 12480603 Jun 2009 US
Child 13167549 US